Brief: Pharming Gets EMA Accelerated Assessment For leniolisib

Pharming

01/08/2022 06:02

Aug 1 (Reuters) - PHARMING GROUP NV  PHAR.AS :
    * PHARMING GROUP RECEIVES ACCELERATED ASSESSMENT IN EUROPE
FOR
LENIOLISIB FOR THE TREATMENT OF RARE IMMUNODEFICIENCY, APDS
    * EMA ACCELERATED ASSESSMENT ALLOWS A SHORTER REVIEW PERIOD
FOR
LENIOLISIB FROM A STANDARD 210 DAYS TO 150 DAYS
    * PHARMING IS ON TRACK TO SUBMIT ITS MARKETING AUTHORISATION
APPLICATION FOR LENIOLISIB IN H2 2022
    * PHARMING IS ON TRACK AND PLANS TO SUBMIT ITS MAA FOR
LENIOLISIB
TO EMA IN OCTOBER 2022

Source text for Eikon:  ID:nCNWcb13ra 
Further company coverage:  PHAR.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))